Yes相关蛋白(YAP)和具有PDZ结合基序(TAZ)的转录共激活因子,可在细胞质和细胞核之间动态穿梭,导致其下游基因表达的抑制或增强。最近出现的证据表明,YAP/TAZ与导致心血管疾病(CVD)的病理生理过程密切相关。在心血管系统中,YAP/TAZ参与一系列生物过程的编排,如氧化应激,炎症,扩散,和自噬。此外,YAP/TAZ已被发现与各种心血管疾病的发生和发展密切相关,包括动脉粥样硬化,肺动脉高压,心肌纤维化,心脏肥大,和心肌病。在这次审查中,我们深入研究了围绕YAP和TAZ的最新研究,以及描述它们在心血管系统中与各种生理过程有关的CVD发病机理中的作用。此外,我们重点介绍了目前针对YAP/TAZ治疗CVDs的潜在药物,并讨论了它们在转化应用方面的挑战.总的来说,这篇综述可能为理解和治疗心血管疾病提供新的见解.
Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) serve as transcriptional co-activators that dynamically shuttle between the cytoplasm and nucleus, resulting in either the suppression or enhancement of their downstream gene expression. Recent emerging evidence demonstrates that YAP/TAZ is strongly implicated in the pathophysiological processes that contribute to cardiovascular diseases (CVDs). In the cardiovascular system, YAP/TAZ is involved in the orchestration of a range of biological processes such as oxidative stress, inflammation, proliferation, and autophagy. Furthermore, YAP/TAZ has been revealed to be closely associated with the initiation and development of various cardiovascular diseases, including atherosclerosis, pulmonary hypertension, myocardial fibrosis, cardiac hypertrophy, and cardiomyopathy. In this
review, we delve into recent studies surrounding YAP and TAZ, along with delineating their roles in contributing to the pathogenesis of CVDs with a link to various physiological processes in the cardiovascular system. Additionally, we highlight the current potential drugs targeting YAP/TAZ for CVDs therapy and discuss their challenges for translational application. Overall, this
review may offer novel insights for understanding and treating cardiovascular disorders.